Molecular markers
Melanoma mutations
PTEN

Author: Joshua Bradish, M.D. (see Authors page)
Editor: Gregory A. Hosler, M.D., Ph.D.

Revised: 12 June 2018, last major update August 2014

Copyright: (c) 2014-2018, PathologyOutlines.com, Inc.

PubMed Search: PTEN[TI] melanoma free full text[sb]

See also: Stains - PTEN
Cite this page: Bradish, J. PTEN. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/molecularpathPTEN.html. Accessed July 20th, 2018.
Definition / general
  • PTEN, phosphatase and tensin homologue, is a tumor suppressor gene located on chromosome 10 which is found in almost all tissues of the body
  • It inhibits the AKT pathway through dephosphorylation of PIP3 to PIP2
  • PTEN normally assists in halting cell division and triggering apoptosis when necessary (Oncogene 2003;22:3113)
Diagrams / tables

Images hosted on other servers:
Missing Image

Activating pathways

Mutations
  • Many different types of PTEN mutations have been described (deletions, frameshift, missense, nonsense, etc.)
  • Loss of PTEN activity causes an upregulation in the AKT pathway
  • Exon 5, the area that encodes for the phosphatase activity, appears to be a hotspot for mutations (Cell Mol Life Sci 2012;69:1475)
Associated findings
Associated histological findings
  • While PTEN loss is found in both nevi as well as melanoma, there are no associated histological findings
Detection methods
  • Immunohistochemistry and FISH can detect deletion or decreased expression of PTEN
  • PCR and next generation sequencing have been used to detect specific PTEN mutations, however, many different mutations have been described (Am J Pathol 2000;157:1123)
Inhibitor therapy
  • No specific targeted therapy against PTEN currently exists
  • Other inhibitors targeting the PI3K / AKT / mTOR pathway may provide some benefit for patients
Mechanisms of resistance
  • No mechanisms of resistance have been evaluated
Resistance therapies
  • No resistance therapies have been evaluated